Two-Year TAXUS-IV Stent Data Show Slight Increase In Thrombosis
This article was originally published in The Gray Sheet
Boston Scientific's Taxus drug-eluting stent is associated with slightly greater long-term thrombosis than the bare-metal Express in the TAXUS-IV study
You may also be interested in...
FDA's public health notification related to adverse events for J&J/Cordis' Cypher is intended to generate further data collection for the drug-eluting stent rather than raise undue concern over clotting issues, the agency says
TAXUS II: Anti-restenotic effects of paclitaxel are maintained beyond the cessation of clopidogrel therapy at six months post-implant, according to twelve-month data from Boston Scientific's trial of the Taxus paclitaxel-eluting stent, presented March 27 by Antonio Columbo, MD, Centro Cuore Columbus, Milan. Target lesion revascularization rates were 4.7% and 3.8% in the slow drug-release and moderate drug-release groups, respectively at 12 months, compared with 14.4% in the control group. One-year follow-up results represent a slight increase in each group over the six-month TLR rates presented in September at the annual TCT meeting in Washington, D.C. (1"The Gray Sheet" Sept. 30, 2002, p. 5)...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.